Auris Medical Holding AG (EARS)
(Delayed Data from NSDQ)
$4.82 USD
-0.32 (-6.23%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.80 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Altamira Therapeutics Ltd. [EARS]
Reports for Purchase
Showing records 1 - 20 ( 26 total )
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
A nasal spray to help protect against COVID-19
Provider: Edison Investment Research Limited
Analyst: JACOBS M
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
AM-201 proof of concept data is weeks away
Provider: Edison Investment Research Limited
Analyst: JACOBS M
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
Full-year results and near-term trial initiations
Provider: Edison Investment Research Limited
Analyst: JACOBS M
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
Initiation of coverage : Treating vertigo
Provider: Edison Investment Research Limited
Analyst: JACOBS M
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
We are dropping coverage of EARS shares to reallocate our research resources
Provider: Roth Capital Partners, Inc.
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
ValuEngine Detailed Valuation Report for EARS
Provider: ValuEngine, Inc
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
We are placing shares of EARS Under Review, and transferring coverage to ROTH Capital Research due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
AM-125 Highlighted at Symposium on Vertigo Therapies
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
All Development Programs On Track; Pivotal Trial Data By YE?17
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Altamira Therapeutics Ltd.
Industry: Medical - Drugs
First of Two AM-111''s Phase 3s Are Enrolled; Reiterate $4.50 PT
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M